---
title: "Family illness identified as FENIB after decades of being called ‘it’"
id: "stat-news-1-opinion-the-inherited-disease-my-family-called-it-had-a-name-which-changed"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-inherited-disease-my-family-called-it-had-a-name-which-changed"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/?utm_campaign=rss"
published_at: "2026-10-22T08:30:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Family illness identified as FENIB after decades of being called ‘it’
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-opinion-the-inherited-disease-my-family-called-it-had-a-name-which-changed
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/?utm_campaign=rss)
- **Published At:** 2026-10-22T08:30:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Three generations of women in the author’s family carried a progressive, unnamed neurological illness that was referred to colloquially as “it.” - The family had documented history spanning roughly 50 years, with clinical descriptions including progressive cognitive decline, seizures, and motor symptoms reported across relatives. - Clinicians repeatedly described the condition as “rare,” “poorly understood,” and “difficult to characterize,” language that normalized uncertainty and discouraged continued inquiry within the family. - The author, a research methodologist with over two decades of experience in systematic reviews and evidence synthesis, initially accepted that lack of a name despite having the skills and access to pursue the literature. - Using contemporary literature and an AI-assisted search, the author matched family clinical features and historic reports to **FENIB** (familial encephalopathy with neuroserpin inclusion bodies), an ultra-rare genetic neurodegenerative disorder long present in the scientific literature. - The source article reports that **FENIB** affects fewer than 1 in 1 million people and has been described in research since the 1980s and 1990s; the author’s family cases appear in the literature, though the family had not been informed. - Naming the condition reorganized the family narrative: the author told her children and can now pass on a diagnostic label rather than a pronoun, altering future clinical and psychosocial decisions. - The piece argues that research accumulates in publications and databases but that infrastructure to notify families or connect them to the literature often fails, leaving affected families uninformed despite active scientific work. - The author notes systemic gaps: lack of follow-up notification to research participants and poor mechanisms connecting historical case reports to living families; these structural deficits are presented as non-malicious but consequential. - The essay references the author’s forthcoming memoir, “Naming It,” and uses the personal narrative to illustrate broader issues in communication between rare-disease research and families living with those conditions.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/?utm_campaign=rss) [ethics](https://www.statnews.com/topic/ethics/) [diagnostics](https://www.statnews.com/topic/diagnostics/) [Medical devices](https://www.statnews.com/topic/medical-devices/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) Opinion[First Opinion](https://www.statnews.com/category/first-opinion/) # The inherited disease my family called ‘it’ had a name, which changed everything ## My children won’t have to grow up with the questions I did * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/Andrea-Carol-Miranda-in-Medford-1990-645x645.jpg) The author, far right, with her sister and mother in 1990.Courtesy Miranda Pappas By Miranda Pappas Oct. 22, 2026 Pappas is a research methodologist with more than two decades of experience evaluating clinical and scientific evidence. The disease didn’t have a name in our house. It had descriptions: the way her hands shook or she lost her words midsentence. The way she could be fully present at breakfast then somewhere unreachable by dinner. And it had a history. My grandmother had died at 29 of what we believed was something similar, my mother had been symptomatic before I was old enough to form the question, my older sister would be told at 26 that she had it, too. What the disease had in our house was a pronoun. “It.” As in, “it got worse over the winter.” As in, “your sister might get it.” As in, “we don’t know much about it.” Advertisement That last sentence was repeated so many times, by so many doctors, that it stopped feeling like an update and started feeling like a fact about the world. Some things were known. This wasn’t one of them. We filed it alongside questions that were genuinely unanswerable, not worth revisiting. We were wrong about that. I just didn’t know it yet. I grew up as the primary caregiver for my mother from roughly age 8‚ managing the household, bridging the gap between what was happening inside our walls and what we presented to the world outside them. By the time I was old enough to understand what I was doing, I had already been doing it for years, not because anyone assigned it to me explicitly but because someone had to and I was there and I was capable, and it turned out that capability was its own kind of assignment. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2026/10/deepa-final-768x432.jpg) ### [A mother-daughter quest to find fellow members of an ultra-rare genetic community](https://www.statnews.com/2026/10/08/rare-disease-nicolaides-baraitser-syndrome-history-ncbrs-researchers/) The disease organized my childhood the way weather organizes a farming life. You don’t fight it, you work around it, you learn its seasons. And somewhere in the years of working around it, you stop asking what it is and start managing what it does. Three generations of women in my family — my grandmother, my mother, my sister — carried the same condition through the same blood before any of us had a clinical word for it. Fifty years of documented family history. Fifty years of doctors who shrugged with genuine sympathy and said, _rare_. _Poorly understood_. _Difficult to characterize_. I believed them for a long time. Here is something worth knowing about the category called rare disease. _Rare_ does not mean _unknown_. It usually means underresearched, underfunded, and underconnected to the people living inside it. There are approximately [7,000 to 10,000 identified rare diseases](https://www.rarediseasesinternational.org/collaborative-global-network/), depending on what [definition](https://rarediseases.org/wp-content/uploads/2023/04/Rare-Disease-Fact-Sheet.pdf) you use. Many of them have names, and many have researchers who have dedicated careers to a single mutation, a single protein, a single entry point into the vast underlit territory of conditions that affect small numbers of people and therefore attract small amounts of attention and money. The work on these diseases gets done‚ slowly, in small labs, by scientists who chose a difficult corner of medicine because something drew them there. The work gets published. The knowledge accumulates. And then, in too many cases, it stays there. There is no architecture reliably connecting what medicine knows about a rare condition to the families living inside it. Research participants from earlier decades have no right to follow-up notification. Families whose cases contributed to literature that eventually named their disease may never know the paper was written. The loop, opened when the family first came to medical attention, can stay open indefinitely on their end. On the other end, in a database they don’t know to search, the loop may have closed years ago. This is not malice, it’s infrastructure, but the cost is real regardless. Advertisement The cost is my mother going through nearly 40 years of illness without being told that someone had looked at what she had and given it a name. The cost is my sister and her 15 years of deterioration and her death at 41, in a world where a researcher somewhere had been asking the same questions we asked in our living room, except the researcher was getting answers and we were not getting calls. I am a research methodologist. For 23 years I have worked at an academic medical center building systematic reviews‚ assembling bodies of medical literature to answer clinical questions, following citation chains, evaluating sources, asking the next question without assuming the answer. I had the skills and the access and I had stopped looking, and that is the sentence I keep coming back to. I had stopped asking the question that mattered most to me personally‚ not because I forgot, not because I stopped caring, but because somewhere in the decades of shrugged answers, I had accepted the not-knowing as the settled state. The doctors had said _rare_ , _poorly understood_ , _difficult to characterize_ for so long that I had internalized their uncertainty as my own. A research methodologist’s skill set and a grieving daughter’s resignation, and the resignation had won. [![](https://www.statnews.com/wp-content/uploads/2026/10/IMG_3671-1024x765.jpg)](https://www.statnews.com/wp-content/uploads/2026/10/IMG_3671-rotated.jpg)The author, her baby son, and her mother.Courtesy Miranda Pappas There is a specific exhaustion that comes from caring for people with unnamed conditions across many years. You ask the questions when they feel fresh. You push when pushing feels possible. And then the decades accumulate and the people you were asking on behalf of are gone, and you are left with your own life to build from whatever remains, and the unanswered questions stop feeling like questions and start feeling like the way of things. I’ve written a memoir about all of this called “Naming It.” After finishing the memoir, I sat down with the oldest document I had, my grandmother’s death certificate, which my aunt mailed me 20 years ago. I looked at it many times without understanding it, because I had not yet learned how to read it. Going through it to check a fact I stopped on cause of death: acute coronary thrombosis. A [catch all](https://www.cdc.gov/nchs/data/nvss/handbook/2023-physicians-mcod-handbook.pdf). It was not an answer. It was a placeholder. It still is. In 1954, though, differential diagnosis capabilities were limited and no one looked further. Advertisement Using Claude I typed in everything I knew about what came after my grandmother’s death and my family’s history, along with the research from the ’80s and ’90s. Within seconds it answered what decades of shrugs had not. The research had worked, comparisons were made, and “it” had a name: [FENIB](https://rarediseases.org/rare-diseases/familial-encephalopathy-with-neuroserpin-inclusion-bodies/), an ultra-rare genetic neurodegenerative disorder with progressive dementia and seizures, found in less than 1 in 1 million people. It had been named and studied for years. My family was in the literature. We had seen doctors for years. Still, no one told us. Learning the name did not only answer a question. It reorganized everything behind it, the way a random set of details rearranges the moment you learn the one thing connecting them. I spent my life managing what the disease did. Now I understood what it was. My grandmother handed my mother an inheritance that nobody named. My mother did the same. I can hand my children an inheritance with a name. So I told them. Not in front of a fireplace the way I had pictured it growing up, when I was telling children who did not yet exist how I survived. This time it was at our favorite restaurant on an ordinary Wednesday. I told them everything I discovered over the previous 72 hours. The death certificate, the research, the name: FENIB. For decades the disease in our family had only a pronoun. My children are the first generation to grow up with its name. _Miranda Pappas is a research methodologist with more than two decades of experience evaluating clinical and scientific evidence. She holds a master’s degree in counseling psychology and is the author of the forthcoming memoir “_ _Naming It_ _.”_ * * * ###### Letter to the editor Have an opinion on this essay? [Submit a letter to the editor](https://www.statnews.com/submit-a-letter-to-the-editor/?subject=The%20inherited%20disease%20my%20family%20called%20%E2%80%98it%E2%80%99%20had%20a%20name,%20which%20changed%20everything). [genetics](https://www.statnews.com/topic/genetics/), [neurology](https://www.statnews.com/topic/neurology/), [neuroscience](https://www.statnews.com/topic/neuroscience/), [rare diseases](https://www.statnews.com/topic/rare-diseases/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. Miranda Pappas ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/First-Opinion-Logo-Black-640x319.png) ### Newsletter The smartest thinkers in life sciences on what's happening — and what's to come Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/https___cdn.sanity.io_images_xq1bjtf4_production_964fa47326a827f12bf336e880b2fdc4665711e6-5973x4480-1-80x80.jpg) [I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/L4A2797-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A German biotech has big ambitions in cancer. Now it needs to get a medicine approved](https://www.statnews.com/2026/10/21/immatics-cancer-cell-therapy-targets-prame-protein/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-491436280-80x80.jpg) [Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary](https://www.statnews.com/2026/10/20/elizabeth-holmes-superpower-authenticity-vs-truth-matt-herper-take/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2301169427-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [CMS extends fraud crackdown to New York’s adult day care program](https://www.statnews.com/2026/10/21/cms-medicaid-fraud-nyc-adult-daycare-operators/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2208174977-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In DOGE’s aftermath, federal health workers bristle at new performance reviews](https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/) 2. ![
## Related Clinical Research

- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)
- [Global dementia incidence projected to reach 24.7 million new cases annually by 2050](https://medichelpline.com/clinical-feed/medical-news-today-0-dementia-cases-to-double-by-2050-why-women-some-countries-may-be-at-higher-risk.md)
- [Optogenetics shows early promise for restoring vision in retinitis pigmentosa](https://medichelpline.com/clinical-feed/stat-news-0-stat-in-small-trial-optogenetics-restores-some-vision-lost-to-retinitis.md)
- [Exon‑skipping therapy for Duchenne muscular dystrophy offers benefit to a small subset of patients](https://medichelpline.com/clinical-feed/stat-news-2-stat-in-duchenne-muscular-dystrophy-a-promising-therapy-is-available-to-a.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.